View Archive »
About The Cover
Paclitaxel inhibition of cell migration. A mixed culture of wild-type CHO cells and HAβ3-5 cells was scratched to make a wound and the cells were allowed to migrate for 24 h in the absence or presence of 10 nM paclitaxel. The cells were then stained for α-tubulin (red), HAβ3-tubulin (green), and DNA (blue). See Ganguly et al.
|
|
Table of Contents
|
| Mycoplasmas and Human prostate cancer: An exciting but cautionary note |
|
https://doi.org/10.18632/oncotarget.282
|
| 352-355 |
|
| Proteotoxic stress targeted therapy PSTT |
|
https://doi.org/10.18632/oncotarget.284
|
| 356-357 |
Brief Reports
|
| Xenotropic murine leukemia virusrelated virus XMRV in prostate cancer cells likely represents a laboratory artifact |
|
https://doi.org/10.18632/oncotarget.287
|
| 358-362 |
Research Papers
|
| Netrin1 overexpression is predictive of ovarian malignancies |
|
https://doi.org/10.18632/oncotarget.258
|
| 363-367 |
|
| Class III βTubulin Counteracts the Ability of Paclitaxel to Inhibit Cell Migration |
|
https://doi.org/10.18632/oncotarget.250
|
| 368-377 |
|
| Network Modeling of MDM2 InhibitorOxaliplatin Combination Reveals Biological Synergy in wtp53 solid tumors |
|
https://doi.org/10.18632/oncotarget.269
|
| 378-392 |
|
| No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis |
|
https://doi.org/10.18632/oncotarget.278
|
| 393-400 |
Research Perspectives
|
| YB1 drives preneoplastic progression: Insight into opportunities for cancer prevention |
|
https://doi.org/10.18632/oncotarget.276
|
| 401-406 |
|
| Casein kinase 2 phosphorylation of Hsp90 threonine 22 modulates chaperone function and drug sensitivity |
|
https://doi.org/10.18632/oncotarget.272
|
| 407-417 |
|
| Novel insights into the synergistic interaction of Bortezomib and TRAIL: tBid provides the link |
|
https://doi.org/10.18632/oncotarget.277
|
| 418-421 |
|
| cJUN prevents methylation of p16INK4a and Cdk6: the villain turned bodyguard |
|
https://doi.org/10.18632/oncotarget.279
|
| 422-427 |
Copyright © 2026 Rapamycin Press LLC dba Impact Journals
Oncotarget ® is a registered trademark of Rapamycin Press LLC
Impact Journals ® is a registered trademark of Rapamycin Press LLC
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLC